Physician profile
Heather D Jimenez
NPI 1912429184
$1,019.43
in general payments reported to CMS, 2019-2025
23 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $128 · 2023: $51.40 · 2024: $256 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.74 | 2021-2025 | Wegovy |
| Dexcom, INC. | $101.06 | 2024-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $85.73 | 2021-2023 | Resonate El Icd Vr |
| Lilly USA, LLC | $78.23 | 2024-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $63.14 | 2021-2023 | Myrbetriq |
| Pfizer INC. | $56.75 | 2024 | |
| Glaxosmithkline, LLC. | $46.86 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $43.17 | 2021 | |
| Sanofi Pasteur INC. | $42.43 | 2022 | |
| Abbott Laboratories | $35.84 | 2021 | |
| Inspire Medical Systems, INC. | $34.38 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $24.31 | 2025 | |
| Esperion Therapeutics, INC. | $23.73 | 2021 | |
| Viiv Healthcare Company | $21.60 | 2024 | Apretude |
| Dynavax Technologies Corporation | $20.69 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.82 | 2021 | |
| Exact Sciences Corporation | $18.15 | 2025 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $17.05 | 2024 | |
| Sunovion Pharmaceuticals INC. | $17.02 | 2021 | |
| Amgen INC. | $16.06 | 2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $15.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.73 | 2021 | |
| Currax Pharmaceuticals LLC | $13.46 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.